ROCKVILLE, Md., April 26 /PRNewswire-FirstCall/ -- Protiveris Inc., a bio-
nanotechnology company commercializing nano-mechanical technologies to
facilitate biomolecular research, today announced that it has successfully
completed installation of its VeriScan(TM) 3000 Biosensor System at the
Lombardi Comprehensive Cancer Center at Georgetown University.
Dr. Andrew Quong, who leads the Center's Division of Nanotechnology and
Integrative Cancer Biology in the Department of Oncology, will direct a
collaborative effort to explore the use of nanotechnologies in cancer research
using Protiveris's microcantilever-based products.
"This represents a significant milestone for Protiveris as it is the first
VeriScan System collaboration with specific clinical cancer research
applications," commented Robert Menzi, Chief Operating Officer at Protiveris.
"Dr. Quong and his team at Lombardi are uniquely qualified to develop new
approaches using our nano-technology products. Dr Quong understands the full
range of scientific and technological requirements -- from engineering and
physics to chemistry and biology -- necessary to develop successful and
innovative approaches to cancer research."
"This as a unique opportunity to bring the latest advances in the emerging
field of nanotechnology to cancer diagnosis and therapeutic stratification,"
added Dr Quong. "The Protiveris VeriScan Biosensor System affords us the
potential to perform highly sensitive multiplexed assays for both laboratory
and clinical use on a stable, well engineered platform."
The VeriScan 3000 protein biochip and optical reader utilize arrays of
microcantilevers with customizable surfaces to measure, label-free and in
real-time, multiplex and distinct protein, antibody, antigen, or DNA
biomolecular interactions. Protiveris is currently installing this system in
forward-looking research facilities in the United States and Europe.
About Protiveris, Inc.
Protiveris is committed to establishing the standard of performance for
proteomic research tools. The VeriScan(TM) 3000 bench-top biochip system
measures and analyzes biomolecular and chemical interactions to enable more
efficient and accurate research outcomes. The biochip utilizes arrays of
microcantilevers with customizable surfaces to detect interactions between
proteins, antibodies, antigens, or DNA. This label-free system provides
researchers with the ability to create high content assays that deliver real
time data. More information about Protiveris, their technology, products, and
services can be found at the company's web site at http://www.protiveris.com.
About the Lombardi Comprehensive Cancer Center
Established in 1970, the Lombardi Comprehensive Cancer Center is named for
the legendary Green Bay Packers and Washington Redskins coach Vince Lombardi,
who was treated for cancer at Georgetown University Hospital. What began as a
small clinic grew over the years to become a state-of-the-art cancer center.
In 1990, the Lombardi Center won the designation of "Comprehensive Cancer
Center" from the National Cancer Institute (NCI). To obtain this designation,
a center must meet strict research, clinical trials and community outreach
criteria. In 2003, Lombardi's comprehensive cancer center status was renewed
by the NCI. Lombardi's internationally renowned clinical team offers the
latest treatments for virtually every type of cancer, with a particular
emphasis in solid tumors and adult and pediatric hematologic cancers. More
information about Lombardi Comprehensive Cancer Center can be found at
SOURCE Protiveris Inc.